No hidden fees100% onlineFree fast deliveryUnlimited 24/7 supportFree doctor reviewNo charge until a provider approves
The Peptide Atlas

Semaglutide

A longer-lasting version of GLP-1, a hormone your gut releases when you eat.

Class
GLP-1 receptor agonist
Evidence
Established
Status
FDA-approved (Ozempic, Wegovy); also made by compounding pharmacies.
Forms
Weekly injection; daily tablet

What people use it for

Weight loss, and quieting the constant negotiation with food.

The signal

GLP-1 tells your brain you've had enough and slows your stomach down [1]. Some people get a strong version of that signal and some barely get one, which has a lot to do with why the same meal fills one person up and leaves another one hungry.

How it works

It activates the same receptors as your own GLP-1, but instead of breaking down in a few minutes it stays active for about a week. Appetite drops, you fill up on less food, and for a lot of people the constant background thinking about food quiets down [2].

What the research shows

One of the most heavily studied drugs of the past decade. In the STEP 1 trial, adults lost 14.9% of their body weight on average over 68 weeks [3]. A later trial in people who already had heart disease also showed fewer heart attacks and strokes [4].

What people get wrong

That needing it means you failed at willpower. Appetite is mostly hormones, and people start from very different baselines. Also that stopping means gaining it all back automatically. Your appetite does come back when you stop, so keeping the weight off takes an actual plan, whether that's a maintenance dose, changed habits, or both.

Pepvio prescribes this through licensed U.S. physicians and pharmacies. Pepvio's GLP-1 program

References

  1. Drucker DJ. Diabetologia (2023). The expanding incretin universe: from basic biology to clinical translation. PubMed
  2. Blundell J et al., Diabetes Obes Metab (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. PubMed
  3. Wilding JPH et al., N Engl J Med (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. PubMed
  4. Lincoff AM et al., N Engl J Med (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. PubMed

Last reviewed 2026-08-24. Every reference is verified against the primary literature at review time. How the Atlas grades evidence